Omada Health, Inc. OMDA
Our mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor's visits, providing an engaging, personalized, and integrated experience for the individuals in our programs, which we call our "members." Our care is designed to improve their health while delivering value for the employers, health insurance companies ("health plans"), health systems, pharmacy benefit managers ("PBMs"), and other entities that cover the cost of our programs. Our platform is grounded in evidence and supported by peer-reviewed clinical research and third-party accreditations, which we believe enhances credibility with customers, our reseller partners, and other stakeholders. We differentiate through our human-led, technology-enabled care model, which combines proactive Care Teams with data-driven tools to deliver personalized support at scale. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $260.2M | $169.8M | $122.8M | — |
| Cost of revenue | $89.3M | $66.9M | $52.8M | — |
| Gross profit | $170.9M | $102.9M | $70.0M | — |
| R&D | $40.7M | $35.9M | $33.7M | — |
| SG&A | $52.2M | $42.6M | $36.0M | — |
| Total operating expenses | $182.9M | $146.5M | $136.0M | — |
| Operating income | -$12.0M | -$43.7M | -$66.0M | — |
| Interest expense | $2.5M | $4.5M | $4.7M | — |
| Pre-tax income | -$12.8M | -$47.1M | -$67.5M | — |
| Income tax | $0 | $0 | $0 | — |
| Net income | -$12.8M | -$47.1M | -$67.5M | — |
| EPS, basic | -0.35 | -6.11 | -9.52 | — |
| EPS, diluted | -0.35 | -6.11 | -9.52 | — |
| Shares, diluted (wtd. avg.) | 36.6M | 7.7M | 7.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $222.0M | $76.4M | $115.6M | $168.1M |
| Receivables | $34.6M | $23.4M | — | — |
| Inventory | $4.5M | $3.3M | — | — |
| Total current assets | $272.9M | $113.1M | — | — |
| Property, plant and equipment | $7.9M | $5.6M | — | — |
| Goodwill | $13.2M | $13.2M | — | — |
| Other intangibles | $2.4M | $4.3M | — | — |
| Total assets | $305.4M | $150.9M | — | — |
| Accounts payable | $10.3M | $4.2M | — | — |
| Total current liabilities | $75.7M | $54.0M | — | — |
| Long-term debt | $0 | $29.8M | — | — |
| Total liabilities | $75.7M | $86.3M | — | — |
| Retained earnings | -$456.7M | -$444.0M | — | — |
| Total equity | $229.7M | -$384.4M | -$350.1M | -$293.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | $18.3M | -$34.2M | -$49.7M | — |
| Depreciation and amortisation | $5.5M | $4.8M | $4.4M | — |
| Stock-based compensation | $13.0M | $9.4M | $8.7M | — |
| Capital expenditure | $1.3M | $596.0K | $416.0K | — |
| Investing cash flow | -$5.8M | -$3.9M | -$2.9M | — |
| Financing cash flow | $133.2M | -$1.2M | $179.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-015637.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $122.8M | $169.8M | $260.2M |
| Gross profit | — | $70.0M | $102.9M | $170.9M |
| Net income | — | -$67.5M | -$47.1M | -$12.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8000
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LFST | LifeStance Health Group, Inc. | $4.94B | — | 13.9% |
| PRVA | Privia Health Group, Inc. | $2.86B | 124.5x | 22.3% |
| WGS | GeneDx Holdings Corp. | $1.67B | — | 40.0% |
| PNTG | Pennant Group, Inc. | $1.46B | 49.9x | 36.3% |
| USPH | U S PHYSICAL THERAPY INC /NV | $1.32B | 62.3x | 16.3% |
| INNV | InnovAge Holding Corp. | $1.30B | — | 11.8% |
| SRTA | Strata Critical Medical, Inc. | $412.3M | 9.3x | 34.3% |
| DCGO | DocGo Inc. | $26.8M | — | -47.7% |